Overview

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to assess the clinical efficacy of talimogene laherparepvec in terms of tumor response rates.
Phase:
Phase 2
Details
Lead Sponsor:
BioVex Limited
Collaborator:
Symbion Research International
Treatments:
Talimogene laherparepvec